These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33711414)

  • 21. The three Es of cancer immunoediting.
    Dunn GP; Old LJ; Schreiber RD
    Annu Rev Immunol; 2004; 22():329-60. PubMed ID: 15032581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reverse immunoediting: When immunity is edited by antigen.
    Merlo A; Dalla Santa S; Dolcetti R; Zanovello P; Rosato A
    Immunol Lett; 2016 Jul; 175():16-20. PubMed ID: 27131431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-Cell Proteomics for Cancer Immunotherapy.
    Li L; Yan S; Lin B; Shi Q; Lu Y
    Adv Cancer Res; 2018; 139():185-207. PubMed ID: 29941105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer Stem Cells Targeting; the Lessons from the Interaction of the Immune System, the Cancer Stem Cells and the Tumor Niche.
    Rajayi H; Tavasolian P; Rezalotfi A; Ebrahimi M
    Int Rev Immunol; 2019; 38(6):267-283. PubMed ID: 31578892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The immunobiology of cancer immunosurveillance and immunoediting.
    Dunn GP; Old LJ; Schreiber RD
    Immunity; 2004 Aug; 21(2):137-48. PubMed ID: 15308095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune approaches to the treatment of breast cancer, around the corner?
    Criscitiello C; Esposito A; Gelao L; Fumagalli L; Locatelli M; Minchella I; Adamoli L; Goldhirsch A; Curigliano G
    Breast Cancer Res; 2014 Feb; 16(1):204. PubMed ID: 25774617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling cancer immunoediting in tumor microenvironment with system characterization through the ising-model Hamiltonian.
    Rojas-Domínguez A; Arroyo-Duarte R; Rincón-Vieyra F; Alvarado-Mentado M
    BMC Bioinformatics; 2022 May; 23(1):200. PubMed ID: 35637445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NLRC5: new cancer buster?
    Tang F; Xu Y; Zhao B
    Mol Biol Rep; 2020 Mar; 47(3):2265-2277. PubMed ID: 31925644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy.
    León-Letelier RA; Bonifaz LC; Fuentes-Pananá EM
    J Leukoc Biol; 2019 May; 105(5):915-933. PubMed ID: 30698862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of tumour-specific antigens underlies cancer immunoediting.
    DuPage M; Mazumdar C; Schmidt LM; Cheung AF; Jacks T
    Nature; 2012 Feb; 482(7385):405-9. PubMed ID: 22318517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Antitumor Cytotoxic Response: If the Killer Cells Play the Music, the Microenvironmental Hypoxia Plays the Tune.
    Chouaib S
    Crit Rev Immunol; 2020; 40(2):157-166. PubMed ID: 32749093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment.
    Gao S; Yang X; Xu J; Qiu N; Zhai G
    ACS Nano; 2021 Aug; 15(8):12567-12603. PubMed ID: 34339170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor-Derived Extracellular Vesicles in Cancer Immunoediting and Their Potential as Oncoimmunotherapeutics.
    Najaflou M; Shahgolzari M; Khosroushahi AY; Fiering S
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue-Resident Memory T Cells in Cancer Immunosurveillance.
    Park SL; Gebhardt T; Mackay LK
    Trends Immunol; 2019 Aug; 40(8):735-747. PubMed ID: 31255505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy.
    Pérez-Romero K; Rodríguez RM; Amedei A; Barceló-Coblijn G; Lopez DH
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32752264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The mitochondrial dynamics in cancer and immune-surveillance.
    Simula L; Nazio F; Campello S
    Semin Cancer Biol; 2017 Dec; 47():29-42. PubMed ID: 28655520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy.
    Liu Z; Ren Y; Weng S; Xu H; Li L; Han X
    Front Immunol; 2022; 13():809761. PubMed ID: 35140720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy.
    Li X; Shao C; Shi Y; Han W
    J Hematol Oncol; 2018 Feb; 11(1):31. PubMed ID: 29482595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges and prospects of immunotherapy as cancer treatment.
    Rescigno M; Avogadri F; Curigliano G
    Biochim Biophys Acta; 2007 Sep; 1776(1):108-23. PubMed ID: 17720322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.